| Flat View | Saturday, April 04, 2026 |
|
| October 2012 | November 2012 | December 2012 |
| Thursday, November 01, 2012 |
 |
MicroRNAs & Single Molecule Biology Europe - 2012 Symposium ( 9:00 am )
GeneExpression Systems of USA and University of Cambridge of UK
Appasani Research Conferences (ARCEI.ORG)
Jointly Presents
MicroRNAs & Single Molecule Biology Europe - 2012 Symposium
Seventh International
MicroRNAs Europe 2012 Meeting
on
MicroRNAs: Biology to Development and Disease
Second International
Single Molecule Biology Europe 2012 Meeting
on
Molecular Imaging to Single Molecule Analysis
November 1 - 2, 2012
Venue: Peterhouse, University of Cambridge, Cambridge, UK
Meeting Place:
The Venue Peterhouse (middle) is the oldest College of the University of Cambridge, founded in 1284 and an institution dedicated to education and research. Throughout its history, Petreans have been at the heart of the political, social and religious controversies that have shaped today’s society. Some of the influential Petreans include: Henry Cavendish, Lord Kelvin, Sir Frank Whittle and Christopher Cockerill, and Nobel Laureates – Sir John Kendrew, Sir Aaron Klug, Archer Martin and Max Perutz , who gave a twentieth century lead in the field of Molecular Biology. Since many centuries it remained as a hub for innovation and successive generations of the brightest young people around the world.
Why do you wait to join for an intellectual gathering in the ‘microRNomics’ & 'Single Moleclue Biology' arenas at the prestigious college Peterhouse in the Premier University campus!
| Expected Maximum Capacity: |
| Target Audience |
100 |
| Total Speaker Presentations: |
30 |
| Total Poster Presentations: |
10 |
| Total Exhibit Booths: |
5 |
Thursday, November 1, 2012 8:00A.M: Registration Open 9.00 AM – 6.00 PM Scientific Sessions Friday November 2, 2012 8:00A.M: Registration Open 9.00 AM – 6.00 PM Scientific Sessions
Contact Info : GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
Email :
Url: http://www.expressgenes.com
| |
| Friday, November 02, 2012 |
|
MicroRNAs & Single Molecule Biology Europe - 2012 Symposium ( 9:00 am )
GeneExpression Systems of USA and University of Cambridge of UK
Appasani Research Conferences (ARCEI.ORG)
Jointly Presents
MicroRNAs & Single Molecule Biology Europe - 2012 Symposium
Seventh International
MicroRNAs Europe 2012 Meeting
on
MicroRNAs: Biology to Development and Disease
Second International
Single Molecule Biology Europe 2012 Meeting
on
Molecular Imaging to Single Molecule Analysis
November 1 - 2, 2012
Venue: Peterhouse, University of Cambridge, Cambridge, UK
Meeting Place:
The Venue Peterhouse (middle) is the oldest College of the University of Cambridge, founded in 1284 and an institution dedicated to education and research. Throughout its history, Petreans have been at the heart of the political, social and religious controversies that have shaped today’s society. Some of the influential Petreans include: Henry Cavendish, Lord Kelvin, Sir Frank Whittle and Christopher Cockerill, and Nobel Laureates – Sir John Kendrew, Sir Aaron Klug, Archer Martin and Max Perutz , who gave a twentieth century lead in the field of Molecular Biology. Since many centuries it remained as a hub for innovation and successive generations of the brightest young people around the world.
Why do you wait to join for an intellectual gathering in the ‘microRNomics’ & 'Single Moleclue Biology' arenas at the prestigious college Peterhouse in the Premier University campus!
| Expected Maximum Capacity: |
| Target Audience |
100 |
| Total Speaker Presentations: |
30 |
| Total Poster Presentations: |
10 |
| Total Exhibit Booths: |
5 |
Thursday, November 1, 2012 8:00A.M: Registration Open 9.00 AM – 6.00 PM Scientific Sessions Friday November 2, 2012 8:00A.M: Registration Open 9.00 AM – 6.00 PM Scientific Sessions
Contact Info : GeneExpression Systems, Inc.
P.O. Box 540170
Waltham, MA 02454 USA
Tel: (781) 891-8181
Fax: (781)730-0700 or (781) 891-8234
Email :
Url: http://www.expressgenes.com
| |
| Monday, November 05, 2012 |
|
Clinical Trials In CNS ( All Day )
The SMi Group is proud to present their 11th annual Clinical Trials in CNS conference that will discuss the latest developments in preclinical discovery, clinical trial design, clinical trial management and neurodegenerative treatments.
With increasing average life expectancy, these wide range of disorders (from Alzheimer’s, to Parkinson’s, MS, dementia and depression), are becoming increasingly widespread in the population, creating an ever- greater need for new treatments and therapies.
Key reasons to attend:
Learn of the latest drug developments combating the key diseases in CNS, from Alzheimer's and dementia, to depression and schizophrenia
Discuss the cutting issues of the industry, from the ethics of outsourcing, to proving efficacy
Explore the latest innovations in pre-clinical discovery, trial optimisation and biomarker identification
Discover new ways to manage and adapt a clinical trial to ensure its success and efficiency Network with key members of the industry involved in every part of clinical trials: from bench to bedside
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Wednesday 7th November, Copthorne Tara Hotel, 2012
A: Ensuring efficiency and communication in partnerships within CNS clinical trials Lori Wright, President & CEO, Thievon-Wright Consulting Group
Steve Satek, Senior Vice President, Thievon-Wright Consulting Group
8.30 – 12.30pm
B: Ethical decision making in clinical drug development
Michael Emanuel, Managing Director, SintoPharm
13.00 – 5.00pm
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/clinicaltrials-research37.asp
| |
| Tuesday, November 06, 2012 |
|
Clinical Trials In CNS ( All Day )
The SMi Group is proud to present their 11th annual Clinical Trials in CNS conference that will discuss the latest developments in preclinical discovery, clinical trial design, clinical trial management and neurodegenerative treatments.
With increasing average life expectancy, these wide range of disorders (from Alzheimer’s, to Parkinson’s, MS, dementia and depression), are becoming increasingly widespread in the population, creating an ever- greater need for new treatments and therapies.
Key reasons to attend:
Learn of the latest drug developments combating the key diseases in CNS, from Alzheimer's and dementia, to depression and schizophrenia
Discuss the cutting issues of the industry, from the ethics of outsourcing, to proving efficacy
Explore the latest innovations in pre-clinical discovery, trial optimisation and biomarker identification
Discover new ways to manage and adapt a clinical trial to ensure its success and efficiency Network with key members of the industry involved in every part of clinical trials: from bench to bedside
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Wednesday 7th November, Copthorne Tara Hotel, 2012
A: Ensuring efficiency and communication in partnerships within CNS clinical trials Lori Wright, President & CEO, Thievon-Wright Consulting Group
Steve Satek, Senior Vice President, Thievon-Wright Consulting Group
8.30 – 12.30pm
B: Ethical decision making in clinical drug development
Michael Emanuel, Managing Director, SintoPharm
13.00 – 5.00pm
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/clinicaltrials-research37.asp
| |
| Wednesday, November 07, 2012 |
|
Clinical Trials In CNS ( All Day )
The SMi Group is proud to present their 11th annual Clinical Trials in CNS conference that will discuss the latest developments in preclinical discovery, clinical trial design, clinical trial management and neurodegenerative treatments.
With increasing average life expectancy, these wide range of disorders (from Alzheimer’s, to Parkinson’s, MS, dementia and depression), are becoming increasingly widespread in the population, creating an ever- greater need for new treatments and therapies.
Key reasons to attend:
Learn of the latest drug developments combating the key diseases in CNS, from Alzheimer's and dementia, to depression and schizophrenia
Discuss the cutting issues of the industry, from the ethics of outsourcing, to proving efficacy
Explore the latest innovations in pre-clinical discovery, trial optimisation and biomarker identification
Discover new ways to manage and adapt a clinical trial to ensure its success and efficiency Network with key members of the industry involved in every part of clinical trials: from bench to bedside
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Wednesday 7th November, Copthorne Tara Hotel, 2012
A: Ensuring efficiency and communication in partnerships within CNS clinical trials Lori Wright, President & CEO, Thievon-Wright Consulting Group
Steve Satek, Senior Vice President, Thievon-Wright Consulting Group
8.30 – 12.30pm
B: Ethical decision making in clinical drug development
Michael Emanuel, Managing Director, SintoPharm
13.00 – 5.00pm
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/clinicaltrials-research37.asp
| |
| Wednesday, November 28, 2012 |
|
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
| Thursday, November 29, 2012 |
|
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
|
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
| Friday, November 30, 2012 |
|
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
|
Diabetes, Cardiovascular & Renal Complications ( 8:30 am )
Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include:
Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
Review clinical results from the DEMAND study
Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation
Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include:
Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis
Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim
James F. List, Vice President, Full Development, Bristol-Myers Squibb
Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca
Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline
Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare
Contact Info : Ninica Hussain
+44 0 207 827 6186
Email :
Url: http://www.smi-online.co.uk/goto/diabetes-conference36.asp
| |
|
|
